Roivant Pipeline Gains Momentum After Mosliciguat Phase II Data

Roivant Sciences highlighted a clinical pipeline anchored by Phase II mosliciguat data at the 12th Annual Cantor Fitzgerald Global Healthcare Conference, as Chief Executive Matt Gline pointed to operational capacity as the firm's primary constraint. Shares of Roivant (ROIV) closed at $40.94, down 2.08% from their previous close of $41.81, as of September 10, 2026, according to Finnhub market data.

"That data kind of catapults mosliciguat into a core pillar of our long-term value alongside brepocitinib and IMVT-1402," said Matt Gline, Chief Executive Officer, Roivant Sciences, during the conference presentation.

Mosliciguat Acquisition and Clinical Profile

Roivant acquired mosliciguat from Bayer for approximately $15 million, securing patent protection that extends into the mid-2040s, according to the Cantor Fitzgerald conference transcript. Management noted that the candidate produced what they characterized as the deepest pulmonary vascular resistance reduction ever observed in a pulmonary hypertension study.

The therapy now shares lead-asset status alongside brepocitinib and IMVT-1402 within Roivant's development portfolio. The company's business model relies on forming subsidiary entities to advance acquired drug candidates through clinical trials.

Commercial Launch and Pipeline Ownership

The company's dermatomyositis treatment brepocitinib, marketed under the brand name LISRAYA, received U.S. Food and Drug Administration approval and launched approximately two weeks prior to the Cantor conference. Street analysts estimate peak sales for the treatment will reach between $2 billion and $4 billion.

Roivant maintains majority stakes across its operating units, holding a 60% ownership interest in Immunovant and a 75% stake in Priovant, with pharmaceutical giant Pfizer owning the remaining 25% of Priovant.

Operational Bottlenecks Over Funding

Despite having multiple assets advancing toward late-stage development, Gline told conference attendees that capital availability is no longer the primary hurdle for the organization. Instead, running multiple Phase III clinical trials simultaneously represents the core operational bottleneck for the clinical pipeline.

The distinction highlights a shift for the biopharmaceutical firm as it transitions several wholly owned and subsidiary programs into broader commercial and late-stage clinical phases.